Corporate Profile

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programsRead More

Stock Information

XCUR (Common Stock) $2.25 Stock is Down 0.1 (4.26%)Data as of 03/22/19 3:45 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart

Stock chart for: XCUR.PK.  Currently trading at $2.25 with a 52 week high of $6.50 and a 52 week low of $2.00.

Press Releases

Upcoming Events

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet